Azetidine → 1-methylcyclopropyl 4-[(1R,2S)-2-(2-{4-[2-(azetidin-1-yl)-2-oxoethyl]-3-fluorophenoxy}ethyl)cyclopropyl]piperidine-1-carboxylate
Reaction equation
[F:1][C:2]1[CH:7]=[C:6]([O:8][CH2:9][CH2:10][C@@H:11]2[CH2:13][C@@H:12]2[CH:14]2[CH2:19][CH2:18][N:17]([C:20]([O:22][C:23]3([CH3:26])[CH2:25][CH2:24]3)=[O:21])[CH2:16][CH2:15]2)[CH:5]=[CH:4][C:3]=1[CH2:27][C:28]([OH:30])=O.[NH:31]1[CH2:34][CH2:33][CH2:32]1.C(N(CC)C(C)C)(C)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CN(C=O)C>[N:31]1([C:28](=[O:30])[CH2:27][C:3]2[CH:4]=[CH:5][C:6]([O:8][CH2:9][CH2:10][C@@H:11]3[CH2:13][C@@H:12]3[CH:14]3[CH2:15][CH2:16][N:17]([C:20]([O:22][C:23]4([CH3:26])[CH2:24][CH2:25]4)=[O:21])[CH2:18][CH2:19]3)=[CH:7][C:2]=2[F:1])[CH2:34][CH2:33][CH2:32]1Participants
6
Reactant 4
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of (2-fluoro-4-{2-[(1S,2R)-2-(1-{[(1-methylcyclopropyl)oxy]carbonyl}piperidin-4-yl)cyclopropyl]ethoxy}phenyl)acetic acid (100 mg, 0.238 mmol) in 1 ml anhydrous DMF at RT was added azetidine (16.3 mg, 0.286 mmol) and N,N-diisopropylethylamine (0.125 ml, 0.715 mmol). o-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (181 mg, 0.477 mmol) was added into the solution and stirred at RT for 4 hrs. The reaction mixture was filtered and purified by reverse-phase HPLC (SunFire Prep C18 OBD 5 um 19×100 mm column; 35-95% acetonitrile in 0.1% formic acid in water gradient) to give the title compound. LC/MS (m/z): 459.3 (M+H)+. GPR119 Human EC50: 3.3 nM
Workup
- filtrationThe reaction mixture was filtered
- custompurified by reverse-phase HPLC (SunFire Prep C18 OBD 5 um 19×100 mm column; 35-95% acetonitrile in 0.1% formic acid in water gradient)
Sources & evidence
- ORD record
- ord-2d97a5256fae4690a8e67c233611084d
- Source dataset
- uspto-grants-2015_02
- Patent number
- US08957062B2
Reaction notes
Loading…